公司資料
TScan Therapeutics, Inc. 股價、新聞與催化劑
- 股票代碼:
- TCRX
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
0.33 USD (+6.00%)
收盤價
最後更新: 2026年9月21日
64M USD
市值
股價為何變動
截至 2026年9月21日，TCRX 上漲 6.00%，收於 $0.3306。目前新聞監測窗口內未發現新的同公司新聞。
公司概覽
業務概覽
TScan Therapeutics is a cell-therapy company focused on T-cell receptor therapies for cancer. Its platform aims to create engineered T cells that can recognize tumor-specific targets.
所在地與產業分類
Headquartered in the United States and listed on NASDAQ, TScan sits in advanced cell therapy.
商業模式特徵
The company depends on clinical validation, manufacturing execution, and the ability to develop a differentiated TCR platform.
生技產業定位
TScan is a high-catalyst cell-therapy name whose stock is highly sensitive to translational progress.
未來催化劑
- TScan’s catalysts are TCR-engineered cell therapy data and any update that shows the platform can handle solid tumors as well as hematologic disease. The stock will move if the clinical story keeps improving.
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。